Nasal mucosal humoral responses to SARS-CoV-2 vaccination priming schedules in the UK: a substudy of the Com-COV single-blind, randomised, non-inferiority trial
The Lancet Microbe · 2026-11 · 101560
DOI: 10.1016/j.lanmic.2026.101560 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Lancet Microbe, 2026-11. Verfasst von Robert H Shaw und 11 weiteren Autor:innen. Beteiligte Einrichtung: Oxford Vaccine Group, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: robert.shaw…. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: University of Oxford John Fell Fund, National Institute for Health and Care Research.
Abstract (Originalsprache)
BACKGROUND: Mucosal surfaces form the first line of defence against respiratory pathogens. Most licensed COVID-19 vaccines are delivered intramuscularly and elicit strong systemic immunity. Whether such vaccines generate locally derived nasal mucosal responses remains uncertain. In this substudy, we aimed to investigate mucosal and systemic antibody responses following different intramuscular SARS-CoV-2 priming vaccination schedules. METHODS: In the Com-COV single-blind, randomised, non-inferiority trial, adults aged 50 years or older who were COVID-19 unvaccinated and SARS-CoV-2 infection-naive were enrolled across eight sites in the UK between Feb 11, 2021, and Feb 26, 2021. Participants were randomised to receive homologous or heterologous vaccination schedules using ChAdOx1 nCoV-19 (ChAd) and BNT162b2 (BNT), administered at either a 28-day or 84-day interval. This substudy collected nasal lining fluid using nasosorption strips in long-interval cohorts. Anti-spike and anti-nucleocapsid IgG and IgA were quantified in serum and nasal samples by electrochemiluminescence immunoassay. Correlations were assessed using Pearson's coefficients. FINDINGS: Mucosal lining fluid samples were collected from 101 participants (mean age 59·1 years [SD 5·0]; 49 [49%] women; 33 [33%] non-White ethnicities). Significant increases in mucosal anti-spike IgA from baseline were seen for ChAd-BNT (geometric mean concentration was 612·8 AU/mL [95% CI 363·6-1032·7]) and BNT-BNT (906·4 AU/mL [619·36-1325·8]). This corresponded to fold rises of 2·78 (1·39-5·54) for ChAd-BNT and 3·11 (1·76-5·50) for BNT-BNT. Mucosal anti-spike IgA trajectories did not mirror vaccination-induced systemic markers, including serum anti-spike IgG (r=0·13, 0·03-0·23, p=0·013). Instead, mucosal anti-spike IgA trajectories correlated with mucosal anti-nucleocapsid IgA (r=0·78, 0·74-0·82, p=5 × 10-77), consistent with mucosal SARS-CoV-2 exposure. Across all schedules, no evidence existed of de novo nasal IgA induction following one or two intramuscular doses, irrespective of baseline serostatus. Observed increases in nasal anti-spike IgA were more consistent with intercurrent mucosal SARS-CoV-2 exposure than direct vaccine effect. Nasal IgG appeared to reflect systemic vaccine responses, whereas SARS-CoV-2 exposure was associated with additional changes in mucosal IgG. INTERPRETATION: Intramuscular immunisation induces robust systemic immunity and remains central to emergency and routine vaccination schedules. However, intramuscular immunisation does not appear to generate de novo local nasal IgA, levels of which have been associated with protection beyond that conferred by serum IgG. Interpretation of vaccine-induced mucosal responses could be confounded by asymptomatic community exposure. Mucosally delivered vaccines are a biologically plausible complementary strategy to enhance protection and reduce transmission, and thus, need further investigation. FUNDING: National Institute for Health Research, the UK Vaccine Taskforce, John Fell Fund, University of Oxford, and Oxfordshire Health Services Research Committee.
Autor:innen und Institutionen
- Oxford Vaccine Group, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK. Electronic address: robert.shaw@paediatrics.ox.ac.uk.
- Oxford Vaccine Group, University of Oxford, Oxford, UK.
- NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of South…
- Oxford Vaccine Group, University of Oxford, Oxford, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK.
- Oxford Vaccine Group, University of Oxford, Oxford, UK; Chinese Academy of Medical Sciences Oxford Institute, University of Oxford, Oxford, UK; Pandemic Sciences Institute, University of Oxford, Oxford, UK.
Förderung
- University of Oxford John Fell Fund
- National Institute for Health and Care Research
Zitieren
APA
Shaw, R. H., Dinesh, T., Alderson, J., Belij-Rammerstorfer, S., Bibi, S., Clutterbuck, E. A., Faust, S. N., Ramasamy, M. N., Snape, M. D., Liu, X., Lambe, T., & Com-COV study group (2026). Nasal mucosal humoral responses to SARS-CoV-2 vaccination priming schedules in the UK: a substudy of the Com-COV single-blind, randomised, non-inferiority trial. The Lancet Microbe, 101560. https://doi.org/10.1016/j.lanmic.2026.101560
Vancouver
Shaw RH, Dinesh T, Alderson J, Belij-Rammerstorfer S, Bibi S, Clutterbuck EA, et al. Nasal mucosal humoral responses to SARS-CoV-2 vaccination priming schedules in the UK: a substudy of the Com-COV single-blind, randomised, non-inferiority trial. The Lancet Microbe. 2026:101560. doi:10.1016/j.lanmic.2026.101560
BibTeX
@article{Shaw2026,
author = {Shaw, Robert H and Dinesh, Tanya and Alderson, Jennifer and Belij-Rammerstorfer, Sandra and Bibi, Sagida and Clutterbuck, Elizabeth A and Faust, Saul N and Ramasamy, Maheshi N and Snape, Matthew D and Liu, Xinxue and Lambe, Teresa and Com-COV study group, Com-COV study group},
title = {Nasal mucosal humoral responses to SARS-CoV-2 vaccination priming schedules in the UK: a substudy of the Com-COV single-blind, randomised, non-inferiority trial},
journal = {The Lancet Microbe},
year = {2026},
pages = {101560},
doi = {10.1016/j.lanmic.2026.101560}
}
EUVIMED